А Russian company Generium has been granted approval by the Ministry of Health to carry out a clinical study on GNR-086 (canakinumab), a counterpart of Ilaris, the original drug by Novartis. As it says in State Register of Medicinal Remedies, there are plans to conduct a comparative analysis of the clinical effectiveness of GNR-086 and Ilaris in patients suffering from adult Still’s disease who are undergoing repeated treatment. Presumably, the trials will end in 2026.
The drug will be administered to patients in parallel groups as subcutaneous injections. The tests will be conducted in 13 medical centers situated in Moscow, St. Petersburg, Yaroslavl, Novosibirsk, Smolensk, Orenburg, Kemerovo, Volgograd, Vladimir, and Chelyabinsk.
The medication Canakinumab is highly effective in treating systemic juvenile idiopathic arthritis and active Still’s disease, including the one that affects adults. This monoclonal antibody specifically targets interleukin-1 beta in humans. It does not react with other members of the interleukin-1 family, such as interleukin-1 alpha.
